Boston Scientific executive Dave Pierce sees a bright future for the company’s GI endoscopy and urology technologies.
As many companies did, Boston Scientific (NYSE:BSX) had to adapt during the COVID-19 pandemic and, with the lessons learned, it may be better for it.
Dave Pierce, the EVP of Boston Scientific’s MedSurg segment, certainly thinks so.
“Our team has really persevered and performed at a high level despite all the uncertainty of the past year,” Pierce told MassDevice following the release of the company’s second-quarter financial results. “We as a company are really proud of how we’ve worked to make a safe environment, give employees what they need from a mental health standpoint and help everyone navigate through the uncertainty of the pandemic.”
